<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04417699</url>
  </required_header>
  <id_info>
    <org_study_id>CRP18085</org_study_id>
    <nct_id>NCT04417699</nct_id>
  </id_info>
  <brief_title>SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer</brief_title>
  <acronym>SHORT</acronym>
  <official_title>SHORT: SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer, a Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benaroya Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Virginia Mason Hospital/Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Benaroya Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      TASOX can be safely and efficaciously delivered after short course radiation, resulting in&#xD;
      significant pathologic downstaging, allowing for an R0 pelvic resection, and providing local&#xD;
      control in appropriately selected stage II/III rectal cancer patients treated with&#xD;
      contemporary TME-based surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase II study patients will be treated with short-course preoperative irradiation&#xD;
      (25 Gy in five fractions of 5 Gy) followed by 6 (six) 2-week cycles of TASOX followed by&#xD;
      total mesorectal excision (TME) for patients with resectable rectal cancer (clinical T3c/dN0,&#xD;
      T3c/dN1, T2N1). Eligible study subjects include adults who are candidates for curative intent&#xD;
      sphincter-sparing surgery and lack high risk features such as tumor encroaching upon the&#xD;
      mesorectal-fascia or low tumors who need an Abdominal-Perineal Resection (APR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Achieve a reduction by at least 5.8 in Neoadjuvant Response (NAR) score compared to historic controls with NAR of 14.59</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>determine whether pre-operative short-course radiation therapy (SRT) and 6 cycles of TASOX offers condensed radiation and total neoadjuvant therapy for intermediate risk rectal cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>The secondary objective is to describe Incidence of Treatment-Emergent Adverse Events and surgery complications among treated subjects.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>TAS102 plus Oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85mg/m2 IV over 2 hours and TAS-102 (35 mg/m2/dose) orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAS 102</intervention_name>
    <description>Oral medication over Days 1-5</description>
    <arm_group_label>TAS102 plus Oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Administered by intravenous infusion over 2 hours on day 1</description>
    <arm_group_label>TAS102 plus Oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age of at least 18 years.&#xD;
&#xD;
          2. Newly diagnosis of rectal adenocarcinoma.&#xD;
&#xD;
          3. ECOG Performance Status (PS): 0, 1 or 2.&#xD;
&#xD;
          4. Candidate for sphincter-sparing surgical resection prior to initiation of neoadjuvant&#xD;
             therapy according to the primary surgeon.&#xD;
&#xD;
          5. Clinical Stage: T1/N1, T2/N1, T3/N1, T3c/dN0.&#xD;
&#xD;
          6. Absence of metastatic disease. Clinical staging is based on physical exam by the&#xD;
             primary surgeon, CT scan of the chest/abdomen, and pelvic MRI.&#xD;
&#xD;
             Node positivity determination: Entry criteria nodes will be measured in short-axis&#xD;
             diameter and for the purposes of study entry will be considered positive if 8 mm or&#xD;
             greater in short axis.&#xD;
&#xD;
             Radiographic N2 status is estimated as: 4 or more nodes that measure 8mm or more in&#xD;
             short-axis.&#xD;
&#xD;
             Radiographic N1 status is estimated as: fewer than 4 lymph nodes that measure 8 mm or&#xD;
             greater in short axis but 1 or more lymph nodes that measure 8 mm or greater.&#xD;
&#xD;
             Nodal Metastatic Disease: nodal stations considered suspicious for metastatic disease&#xD;
             (M1) for rectal cancer are common iliac, external iliac and inguinal nodes.&#xD;
&#xD;
          7. No evidence of tumor that is adherent to the mesorectal fascia and the ability to&#xD;
             perform a curative intent sphincter-sparing TME resection at diagnosis. See exclusion&#xD;
             criterion 4&#xD;
&#xD;
          8. The following laboratory values obtained ≤ 28 days prior to registration.&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
               -  Hemoglobin &gt; 8.0 g/dL&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  SGOT (AST) ≤ 3 x ULN&#xD;
&#xD;
               -  SGPT (ALT) ≤ 3 x ULN&#xD;
&#xD;
               -  Creatinine ≤1.5 x ULN&#xD;
&#xD;
          9. Negative pregnancy test done ≤ 7 days prior to registration, for women of childbearing&#xD;
             potential only.&#xD;
&#xD;
         10. A patient of child-bearing potential is willing to employ adequate contraception. It&#xD;
             includes any of the followings: abstinence, oral contraceptives, implantable hormonal&#xD;
             contraceptives, or double barrier method (diaphragm plus condom). See exclusion&#xD;
             criterion 8&#xD;
&#xD;
         11. Provide informed written consent.&#xD;
&#xD;
         12. Willing to return to enrolling medical site for all study assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical T4 tumors.&#xD;
&#xD;
          2. Clinical N2 disease estimated as four or more lymph nodes that are ≥8 mm.&#xD;
&#xD;
          3. Primary surgeon indicates need for abdominoperineal (APR) at baseline.&#xD;
&#xD;
          4. Evidence that the tumor is adherent to or invading the mesorectal fascia on imaging&#xD;
             studies such that the surgeon would not be able to perform an R0 resection (one with&#xD;
             negative margins).&#xD;
&#xD;
             Distance of the Tumor from the Mesorectal Fascia:&#xD;
&#xD;
             Patients with tumors with a distance of 1mm or less from the mesorectal fascia&#xD;
             reflection have threatened radial margins and are ineligible.&#xD;
&#xD;
          5. Tumor is causing symptomatic bowel obstruction or patients who have had a temporary&#xD;
             diverting ostomy are ineligible.&#xD;
&#xD;
          6. Chemotherapy within 5 years prior to registration. (Hormonal therapy is allowable if&#xD;
             the disease free interval is ≥ 5 years.)&#xD;
&#xD;
          7. Any prior pelvic radiation.&#xD;
&#xD;
          8. Any of the following because this study involves an agent that has known genotoxic,&#xD;
             mutagenic and teratogenic effects:&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Nursing women&#xD;
&#xD;
               -  Men or women of childbearing potential who are unwilling to employ adequate&#xD;
                  contraception&#xD;
&#xD;
          9. Co-morbid illnesses or other concurrent disease which, in the judgment of the treating&#xD;
             investigator obtaining informed consent, would make the patient inappropriate for&#xD;
             entry into this study or interfere significantly with the proper assessment of safety&#xD;
             and toxicity of the prescribed regimens.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Houng Pham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia mason medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lisa A. Kachnic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hagen Kennecke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Houng Pham, MD</last_name>
    <phone>206-223-6801</phone>
    <email>Huong.Pham@virginiamason.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa A. Kachnic, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lisa A. Kachnic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia mason medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huong Pham, MD</last_name>
      <phone>206-223-6801</phone>
      <email>Huong.Pham@virginiamason.org</email>
    </contact>
    <investigator>
      <last_name>Huong Pham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>June 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHORT</keyword>
  <keyword>short course radiation,</keyword>
  <keyword>TASOX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

